{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Schmit N"],"funding":["Medical Research Council","Community Jameel","Wellcome Trust"],"pagination":["RP88283"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC10957170"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["12"],"pubmed_abstract":["Large reductions in the global malaria burden have been achieved, but plateauing funding poses a challenge for progressing towards the ultimate goal of malaria eradication. Using previously published mathematical models of <i>Plasmodium falciparum</i> and <i>Plasmodium vivax</i> transmission incorporating insecticide-treated nets (ITNs) as an illustrative intervention, we sought to identify the global funding allocation that maximized impact under defined objectives and across a range of global funding budgets. The optimal strategy for case reduction mirrored an allocation framework that prioritizes funding for high-transmission settings, resulting in total case reductions of 76% and 66% at intermediate budget levels, respectively. Allocation strategies that had the greatest impact on case reductions were associated with lesser near-term impacts on the global population at risk. The optimal funding distribution prioritized high ITN coverage in high-transmission settings endemic for <i>P. falciparum</i> only, while maintaining lower levels in low-transmission settings. However, at high budgets, 62% of funding was targeted to low-transmission settings co-endemic for <i>P. falciparum</i> and <i>P. vivax</i>. These results support current global strategies to prioritize funding to high-burden <i>P. falciparum</i>-endemic settings in sub-Saharan Africa to minimize clinical malaria burden and progress towards elimination, but highlight a trade-off with 'shrinking the map' through a focus on near-elimination settings and addressing the burden of <i>P. vivax</i>."],"journal":["eLife"],"pubmed_title":["Modeling resource allocation strategies for insecticide-treated bed nets to achieve malaria eradication."],"pmcid":["PMC10957170"],"funding_grant_id":["10.35802/220900","220900/Z/20/Z","MR/R015600/1"],"pubmed_authors":["Winskill P","White MT","Charles GD","Ghani AC","Hauck K","Schmit N","Pianella M","Topazian HM"],"additional_accession":[]},"is_claimable":false,"name":"Modeling resource allocation strategies for insecticide-treated bed nets to achieve malaria eradication.","description":"Large reductions in the global malaria burden have been achieved, but plateauing funding poses a challenge for progressing towards the ultimate goal of malaria eradication. Using previously published mathematical models of <i>Plasmodium falciparum</i> and <i>Plasmodium vivax</i> transmission incorporating insecticide-treated nets (ITNs) as an illustrative intervention, we sought to identify the global funding allocation that maximized impact under defined objectives and across a range of global funding budgets. The optimal strategy for case reduction mirrored an allocation framework that prioritizes funding for high-transmission settings, resulting in total case reductions of 76% and 66% at intermediate budget levels, respectively. Allocation strategies that had the greatest impact on case reductions were associated with lesser near-term impacts on the global population at risk. The optimal funding distribution prioritized high ITN coverage in high-transmission settings endemic for <i>P. falciparum</i> only, while maintaining lower levels in low-transmission settings. However, at high budgets, 62% of funding was targeted to low-transmission settings co-endemic for <i>P. falciparum</i> and <i>P. vivax</i>. These results support current global strategies to prioritize funding to high-burden <i>P. falciparum</i>-endemic settings in sub-Saharan Africa to minimize clinical malaria burden and progress towards elimination, but highlight a trade-off with 'shrinking the map' through a focus on near-elimination settings and addressing the burden of <i>P. vivax</i>.","dates":{"release":"2024-01-01T00:00:00Z","publication":"2024 Feb","modification":"2025-04-22T13:01:54.699Z","creation":"2025-04-06T00:27:08.268Z"},"accession":"S-EPMC10957170","cross_references":{"pubmed":["38329112"],"doi":["10.7554/eLife.88283"]}}